Denise G Alfonso
Examiner (ID: 9637)
Most Active Art Unit | 2662 |
Art Unit(s) | 2662, 2663 |
Total Applications | 95 |
Issued Applications | 36 |
Pending Applications | 47 |
Abandoned Applications | 12 |
Applications
Application number | Title of the application | Filing Date | Status |
---|---|---|---|
Array
(
[id] => 18537779
[patent_doc_number] => 20230242879
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-08-03
[patent_title] => IL-33 SECRETING IMMUNORESPONSIVE CELLS AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/188795
[patent_app_country] => US
[patent_app_date] => 2023-03-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 29408
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -23
[patent_words_short_claim] => 88
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18188795
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/188795 | IL-33 SECRETING IMMUNORESPONSIVE CELLS AND USES THEREOF | Mar 22, 2023 | Pending |
Array
(
[id] => 18019000
[patent_doc_number] => 20220370499
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-11-24
[patent_title] => IMMUNOTHERAPIES FOR TARGETING OF TUMOR VASCULATURE
[patent_app_type] => utility
[patent_app_number] => 17/748997
[patent_app_country] => US
[patent_app_date] => 2022-05-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 15550
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -20
[patent_words_short_claim] => 152
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17748997
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/748997 | IMMUNOTHERAPIES FOR TARGETING OF TUMOR VASCULATURE | May 18, 2022 | Pending |
Array
(
[id] => 18005294
[patent_doc_number] => 20220364060
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-11-17
[patent_title] => ENHANCED METHODS FOR INDUCING AND MAINTAINING NAIVE HUMAN PLURIPOTENT STEM CELLS
[patent_app_type] => utility
[patent_app_number] => 17/744266
[patent_app_country] => US
[patent_app_date] => 2022-05-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 26041
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 60
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17744266
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/744266 | ENHANCED METHODS FOR INDUCING AND MAINTAINING NAIVE HUMAN PLURIPOTENT STEM CELLS | May 12, 2022 | Pending |
Array
(
[id] => 17988815
[patent_doc_number] => 20220354852
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-11-10
[patent_title] => TARGETING WNT SIGNALING FOR IMPROVED GLIOMA IMMUNOTHERAPY
[patent_app_type] => utility
[patent_app_number] => 17/662629
[patent_app_country] => US
[patent_app_date] => 2022-05-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 15767
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -7
[patent_words_short_claim] => 38
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17662629
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/662629 | TARGETING WNT SIGNALING FOR IMPROVED GLIOMA IMMUNOTHERAPY | May 8, 2022 | Pending |
Array
(
[id] => 18058288
[patent_doc_number] => 20220389374
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-12-08
[patent_title] => USE OF FUNCTIONALIZED AND NON-FUNCTIONALIZED ECMS, ECM FRAGMENTS, PEPTIDES AND BIOACTIVE COMPONENTS TO CREATE CELL ADHESIVE 3D PRINTED OBJECTS
[patent_app_type] => utility
[patent_app_number] => 17/738694
[patent_app_country] => US
[patent_app_date] => 2022-05-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 10982
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17738694
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/738694 | USE OF FUNCTIONALIZED AND NON-FUNCTIONALIZED ECMS, ECM FRAGMENTS, PEPTIDES AND BIOACTIVE COMPONENTS TO CREATE CELL ADHESIVE 3D PRINTED OBJECTS | May 5, 2022 | Pending |
Array
(
[id] => 17946054
[patent_doc_number] => 20220333071
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-10-20
[patent_title] => METHODS OF MAKING, EXPANDING AND PURIFYING MIDBRAIN DOPAMINERGIC PROGENITOR CELLS
[patent_app_type] => utility
[patent_app_number] => 17/723026
[patent_app_country] => US
[patent_app_date] => 2022-04-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 10522
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -67
[patent_words_short_claim] => 34
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17723026
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/723026 | METHODS OF MAKING, EXPANDING AND PURIFYING MIDBRAIN DOPAMINERGIC PROGENITOR CELLS | Apr 17, 2022 | Pending |
Array
(
[id] => 17943527
[patent_doc_number] => 20220330544
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-10-20
[patent_title] => SYSTEM, DEVICE, AND METHOD FOR CELL CRYOPRESERVATION VIA SAND-MEDIATED ICE SEEDING
[patent_app_type] => utility
[patent_app_number] => 17/659432
[patent_app_country] => US
[patent_app_date] => 2022-04-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 10155
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 75
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17659432
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/659432 | SYSTEM, DEVICE, AND METHOD FOR CELL CRYOPRESERVATION VIA SAND-MEDIATED ICE SEEDING | Apr 14, 2022 | Pending |
Array
(
[id] => 17946056
[patent_doc_number] => 20220333073
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-10-20
[patent_title] => Compositions and Methods for Generating Gamma-Delta T Cells from Induced Pluripotent Stem Cells
[patent_app_type] => utility
[patent_app_number] => 17/657798
[patent_app_country] => US
[patent_app_date] => 2022-04-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 38313
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -47
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17657798
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/657798 | Compositions and Methods for Generating Gamma-Delta T Cells from Induced Pluripotent Stem Cells | Apr 3, 2022 | Pending |
Array
(
[id] => 17913495
[patent_doc_number] => 20220315890
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-10-06
[patent_title] => NERVE CELL AND APPLICATION THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/709565
[patent_app_country] => US
[patent_app_date] => 2022-03-31
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9689
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 11
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17709565
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/709565 | NERVE CELL AND APPLICATION THEREOF | Mar 30, 2022 | Pending |
Array
(
[id] => 17897329
[patent_doc_number] => 20220306991
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-09-29
[patent_title] => METHODS FOR OBTAINING INDUCED PLURIPOTENT STEM CELLS
[patent_app_type] => utility
[patent_app_number] => 17/704922
[patent_app_country] => US
[patent_app_date] => 2022-03-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9763
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -21
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17704922
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/704922 | METHODS FOR OBTAINING INDUCED PLURIPOTENT STEM CELLS | Mar 24, 2022 | Pending |
Array
(
[id] => 17792569
[patent_doc_number] => 20220251660
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-08-11
[patent_title] => DIAGNOSIS AND TREATMENT OF CARDIOMYOPATHY
[patent_app_type] => utility
[patent_app_number] => 17/669904
[patent_app_country] => US
[patent_app_date] => 2022-02-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 24552
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17669904
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/669904 | DIAGNOSIS AND TREATMENT OF CARDIOMYOPATHY | Feb 10, 2022 | Pending |
Array
(
[id] => 17561716
[patent_doc_number] => 20220125865
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-04-28
[patent_title] => Platform Oncolytic Vector for Systemic Delivery
[patent_app_type] => utility
[patent_app_number] => 17/575787
[patent_app_country] => US
[patent_app_date] => 2022-01-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 40258
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -21
[patent_words_short_claim] => 37
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17575787
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/575787 | Platform Oncolytic Vector for Systemic Delivery | Jan 13, 2022 | Pending |
Array
(
[id] => 17734727
[patent_doc_number] => 20220220186
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-07-14
[patent_title] => CHIMERIC CO-STIMULATORY PROTEINS COMPRISING MUTANT INTRACELLULAR DOMAINS WITH INCREASED EXPRESSION
[patent_app_type] => utility
[patent_app_number] => 17/568189
[patent_app_country] => US
[patent_app_date] => 2022-01-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 33375
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17568189
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/568189 | CHIMERIC CO-STIMULATORY PROTEINS COMPRISING MUTANT INTRACELLULAR DOMAINS WITH INCREASED EXPRESSION | Jan 3, 2022 | Pending |
Array
(
[id] => 17720726
[patent_doc_number] => 20220213446
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-07-07
[patent_title] => METHOD FOR CULTURING CELLS INTO WHICH REPROGRAMMING FACTOR IS INTRODUCED
[patent_app_type] => utility
[patent_app_number] => 17/646398
[patent_app_country] => US
[patent_app_date] => 2021-12-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 17630
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -21
[patent_words_short_claim] => 44
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17646398
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/646398 | METHOD FOR CULTURING CELLS INTO WHICH REPROGRAMMING FACTOR IS INTRODUCED | Dec 28, 2021 | Pending |
Array
(
[id] => 17719038
[patent_doc_number] => 20220211757
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-07-07
[patent_title] => ENGINEERED GAMMA DELTA T CELLS AND METHODS OF MAKING AND USING THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/563482
[patent_app_country] => US
[patent_app_date] => 2021-12-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 17677
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -22
[patent_words_short_claim] => 26
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17563482
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/563482 | ENGINEERED GAMMA DELTA T CELLS AND METHODS OF MAKING AND USING THEREOF | Dec 27, 2021 | Pending |
Array
(
[id] => 17704924
[patent_doc_number] => 20220204930
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-06-30
[patent_title] => PROSTATE CANCER CHIMERIC ANTIGEN RECEPTORS
[patent_app_type] => utility
[patent_app_number] => 17/553391
[patent_app_country] => US
[patent_app_date] => 2021-12-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 58900
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -21
[patent_words_short_claim] => 81
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17553391
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/553391 | Prostate cancer chimeric antigen receptors | Dec 15, 2021 | Issued |
Array
(
[id] => 17688103
[patent_doc_number] => 20220195395
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-06-23
[patent_title] => PHYSIOLOGIC GROWTH OF CULTURED INTESTINAL TISSUE
[patent_app_type] => utility
[patent_app_number] => 17/549028
[patent_app_country] => US
[patent_app_date] => 2021-12-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 10962
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 29
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17549028
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/549028 | PHYSIOLOGIC GROWTH OF CULTURED INTESTINAL TISSUE | Dec 12, 2021 | Pending |
Array
(
[id] => 17655380
[patent_doc_number] => 20220175845
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-06-09
[patent_title] => MULTICISTRONIC MIRNA DELIVERY FOR CARDIAC REPROGRAMMING
[patent_app_type] => utility
[patent_app_number] => 17/541917
[patent_app_country] => US
[patent_app_date] => 2021-12-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8088
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -13
[patent_words_short_claim] => 23
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17541917
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/541917 | MULTICISTRONIC MIRNA DELIVERY FOR CARDIAC REPROGRAMMING | Dec 2, 2021 | Pending |
Array
(
[id] => 17611859
[patent_doc_number] => 20220154138
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-05-19
[patent_title] => METHOD OF PRODUCING PLACENTA-LIKE ORGANOID, PLACENTA-LIKE ORGANOID, AND PRODUCTION OR TEST KIT
[patent_app_type] => utility
[patent_app_number] => 17/530855
[patent_app_country] => US
[patent_app_date] => 2021-11-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11297
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -12
[patent_words_short_claim] => 26
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17530855
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/530855 | METHOD OF PRODUCING PLACENTA-LIKE ORGANOID, PLACENTA-LIKE ORGANOID, AND PRODUCTION OR TEST KIT | Nov 18, 2021 | Abandoned |
Array
(
[id] => 17563495
[patent_doc_number] => 20220127644
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-04-28
[patent_title] => CHIMERIC ANTIGEN RECEPTOR (CAR) NK CELLS AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/511187
[patent_app_country] => US
[patent_app_date] => 2021-10-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 28342
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -21
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17511187
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/511187 | CHIMERIC ANTIGEN RECEPTOR (CAR) NK CELLS AND USES THEREOF | Oct 25, 2021 | Pending |